Aurobindo Pharma Ltd. (NSE: AUROPHARMA) and Glenmark Pharmaceuticals Limited (NSE: GLENMARK) are both listed in the Medicinal Chemicals and Botanical Products industry. Aurobindo Pharma has a market capitalisation of ₹1,05,150 Cr and Glenmark Pharmaceuticals ₹75,556 Cr, as of 16 Nov 2026. Their P/E ratios are 30 and 55.1 respectively. Return on equity is 9.93% for Aurobindo Pharma and 14.07% for Glenmark Pharmaceuticals. Over one year, Aurobindo Pharma's share price is up 59.8% and Glenmark Pharmaceuticals's is up 45.7%.
| Metric | Aurobindo Pharma | Glenmark Pharmaceuticals |
|---|---|---|
| NSE Symbol | AUROPHARMA | GLENMARK |
| BSE Code | 524804 | 532296 |
| Share Price | ₹1,823.20 | ₹2,640.00 |
| Market Cap | ₹1,05,150 Cr | ₹75,556 Cr |
| P/E Ratio | 30 | 55.1 |
| Return on Equity | 9.93% | 14.07% |
| Return on Assets | 5.95% | 14.11% |
| Dividend Yield | 0.00% | 0.19% |
| Beta (1Y) | 0.06 | 0.23 |
| 1-Year Price Change | +59.8% | +45.7% |
| 3-Month Price Change | +9.6% | +13.8% |
| 52-Week Range | ₹1,106.00 – ₹1,859.90 | ₹1,810.00 – ₹2,714.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹10,263 Cr | ₹4,157 Cr |
| Quarterly Net Profit | ₹1,124 Cr | ₹264 Cr |
| Net Margin | 11.0% | 6.3% |
| EPS (Basic, Quarter) | ₹19.57 | ₹9.35 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HI…
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topica…
Aurobindo Pharma has a market capitalisation of ₹1,05,150 Cr, against ₹75,556 Cr for Glenmark Pharmaceuticals as of 16 Nov 2026, about 1.4 times the size by market cap.
Aurobindo Pharma has a P/E of 30 and Glenmark Pharmaceuticals a P/E of 55.1 as of 16 Nov 2026.
Aurobindo Pharma has a return on equity of 9.93% and Glenmark Pharmaceuticals 14.07%.
Aurobindo Pharma's share price is up 59.8% over one year and Glenmark Pharmaceuticals's is up 45.7%.
Aurobindo Pharma reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr for Q2 FY27. Glenmark Pharmaceuticals reported revenue of ₹4,157 Cr and net profit of ₹264 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.